Esperion Therapeutics Files 8-K on Officer/Director Changes
Ticker: ESPR · Form: 8-K · Filed: Apr 4, 2025 · CIK: 1434868
| Field | Detail |
|---|---|
| Company | Esperion Therapeutics, Inc. (ESPR) |
| Form Type | 8-K |
| Filed Date | Apr 4, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes
TL;DR
Esperion 8-K: Leadership changes and financial updates filed April 4, 2025.
AI Summary
Esperion Therapeutics, Inc. filed an 8-K on April 4, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. The filing also includes financial statements and exhibits.
Why It Matters
This filing provides updates on the company's leadership and governance, which can impact strategic direction and investor confidence.
Risk Assessment
Risk Level: low — This is a routine corporate filing detailing leadership and financial information without immediate market-moving news.
Key Players & Entities
- Esperion Therapeutics, Inc. (company) — Registrant
- April 4, 2025 (date) — Date of Report
FAQ
What specific officer or director positions were affected by the changes reported in this 8-K?
The filing indicates changes related to the departure of directors or certain officers, election of directors, and appointment of certain officers, but does not specify the exact positions in the provided text.
Are there any details about new compensatory arrangements for officers mentioned in this filing?
The filing lists 'Compensatory Arrangements of Certain Officers' as an item information, suggesting such arrangements are discussed, but the specifics are not detailed in the provided text.
What is the primary business of Esperion Therapeutics, Inc. according to the filing?
Esperion Therapeutics, Inc. is classified under the Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.
When was Esperion Therapeutics, Inc. incorporated and in which state?
The company was incorporated in Delaware.
What is the principal executive office address for Esperion Therapeutics, Inc.?
The principal executive offices are located at 3891 Ranchero Drive, Suite 150, Ann Arbor, MI 48108.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 4, 2025 regarding Esperion Therapeutics, Inc. (ESPR).